Thirty postmenopausal women with osteoporosis receiving denosumab treatment were randomized to receive either native vitamin D plus calcium supplementation or active Vitamin D3 (eldecalcitol). The outcomes of interest included muscle strength, static and dynamic postural balance, sitting balance, serum biochemical analyses (e.g. 25 hydroxyvitamin D, calcium, phosphorous, creatinine, blood urea nitrogen, etc.) and bone mineral density (BMD). All outcomes were evaluated 6 months post-treatment. The results of this trial demonstrated no statistically significant differences between treatments in terms of muscle strength and balance. However, back extensor strength and knee extensor strength were statistically significantly improved (p<0.05) in the native group when compared to baseline values. Both groups also demonstrated a statistical significant improvement in total length of the trajectory of the center of gravity (LNG) values (p<0.05) compared to baseline at 6-months follow-up. Vitamin D levels in the serum were significantly higher in the native Vitamin D group.